AbbVie's $63 billion mega-deal for Botox-maker Allergan is the pharma industry's latest bet that bigger is better. But the deal is already facing big questions.
This is a Business Insider Prime story. Click the link below to read it.
- No fresh IBC proceedings till December, says Centre
- Bihar Election 2020: EC to announce Bihar assembly poll dates today
- Accenture's Q4 earnings miss estimate with low growth likely to continue for two more quarters
- Top stocks to watch— Tata Consumer, TCS, GAIL, Divi's Laboratories, SBI Life Insurance, ONGC, M&M, RITES and others
- Diabetes drug Metformin at centre of carcinogen-linked recalls in US